Cargando…
1623P Phase I clinical trials (CT) forge on despite COVID-19
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454387/ http://dx.doi.org/10.1016/j.annonc.2021.08.1616 |
| _version_ | 1784570482040766464 |
|---|---|
| author | Bardaji, M.J. Lostes Aliende, E. Moreno, M. Oberoi, H.K. Braña, I. Saavedra, O. Villar, M. Vieito Alonso, G. Galvao, V. Carballo, N. Beltran, M. Rovira, P. Cidoncha, I. Manich, C. Saura Mercade, T. Macarulla Oaknin, A. Galceran, J. Carles Felip, E. Garralda, E. Pujol, S. Perez |
| author_facet | Bardaji, M.J. Lostes Aliende, E. Moreno, M. Oberoi, H.K. Braña, I. Saavedra, O. Villar, M. Vieito Alonso, G. Galvao, V. Carballo, N. Beltran, M. Rovira, P. Cidoncha, I. Manich, C. Saura Mercade, T. Macarulla Oaknin, A. Galceran, J. Carles Felip, E. Garralda, E. Pujol, S. Perez |
| author_sort | Bardaji, M.J. Lostes |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8454387 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84543872021-09-21 1623P Phase I clinical trials (CT) forge on despite COVID-19 Bardaji, M.J. Lostes Aliende, E. Moreno, M. Oberoi, H.K. Braña, I. Saavedra, O. Villar, M. Vieito Alonso, G. Galvao, V. Carballo, N. Beltran, M. Rovira, P. Cidoncha, I. Manich, C. Saura Mercade, T. Macarulla Oaknin, A. Galceran, J. Carles Felip, E. Garralda, E. Pujol, S. Perez Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-09 2021-09-21 /pmc/articles/PMC8454387/ http://dx.doi.org/10.1016/j.annonc.2021.08.1616 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Bardaji, M.J. Lostes Aliende, E. Moreno, M. Oberoi, H.K. Braña, I. Saavedra, O. Villar, M. Vieito Alonso, G. Galvao, V. Carballo, N. Beltran, M. Rovira, P. Cidoncha, I. Manich, C. Saura Mercade, T. Macarulla Oaknin, A. Galceran, J. Carles Felip, E. Garralda, E. Pujol, S. Perez 1623P Phase I clinical trials (CT) forge on despite COVID-19 |
| title | 1623P Phase I clinical trials (CT) forge on despite COVID-19 |
| title_full | 1623P Phase I clinical trials (CT) forge on despite COVID-19 |
| title_fullStr | 1623P Phase I clinical trials (CT) forge on despite COVID-19 |
| title_full_unstemmed | 1623P Phase I clinical trials (CT) forge on despite COVID-19 |
| title_short | 1623P Phase I clinical trials (CT) forge on despite COVID-19 |
| title_sort | 1623p phase i clinical trials (ct) forge on despite covid-19 |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454387/ http://dx.doi.org/10.1016/j.annonc.2021.08.1616 |
| work_keys_str_mv | AT bardajimjlostes 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT aliendee 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT morenom 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT oberoihk 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT branai 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT saavedrao 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT villarmvieito 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT alonsog 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT galvaov 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT carballon 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT beltranm 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT rovirap 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT cidonchai 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT manichcsaura 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT mercadetmacarulla 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT oaknina 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT galceranjcarles 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT felipe 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT garraldae 1623pphaseiclinicaltrialsctforgeondespitecovid19 AT pujolsperez 1623pphaseiclinicaltrialsctforgeondespitecovid19 |